Medivation CEO David Hung fought hard for higher buyout bids. Now, he's set to collect more than $350 million when Pfizer closes its $14 billion deal.

Will Entresto be the megablockbuster that was expected? Early numbers say it isn't so. But Novartis has reason to believe, according to some talk at ESC…

Put another tally in Novartis’ biosimilar win column. The company’s Sandoz generics unit has another FDA approval in hand, this time for its copy of Amgen’s…

As Seqirus hopes to recover from rocky 2016 financials, the company picked up some steam on both sides of the Atlantic this week. Within the span of a few days…

Tuesday, Portola unveiled some solid data for its next-gen anticoagulant reversal agent that may help soften the blow of a recent FDA rejection.

As EU regulators demanded $14.5 billion in back taxes from Apple, a U.S. advocacy group was fighting for similar justice for Gilead--but it wants the U.S. to…

Amgen notched up data for a new Prolia use that could amp up the blockbuster-in-the-making, at a time when the company is bracing for biosimilar rivals to its…

Bristol-Myers Squibb partner Ono Pharmaceutical bagged a third approval in Japan for immuno-oncology drug Opdivo, its most important new product.